

Non-Tyrosine Kinase Inhibitors-North America Market Status and Trend Report 2013-2023

<https://marketpublishers.com/r/N8CA7D10339EN.html>

Date: February 2018

Pages: 145

Price: US\$ 3,480.00 (Single User License)

ID: N8CA7D10339EN

Abstracts

Report Summary

Non-Tyrosine Kinase Inhibitors-North America Market Status and Trend Report 2013-2023 offers a comprehensive analysis on Non-Tyrosine Kinase Inhibitors industry, standing on the readers' perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions answered by this report include:

Whole North America and Regional Market Size of Non-Tyrosine Kinase Inhibitors 2013-2017, and development forecast 2018-2023

Main market players of Non-Tyrosine Kinase Inhibitors in North America, with company and product introduction, position in the Non-Tyrosine Kinase Inhibitors market
Market status and development trend of Non-Tyrosine Kinase Inhibitors by types and applications

Cost and profit status of Non-Tyrosine Kinase Inhibitors, and marketing status

Market growth drivers and challenges

The report segments the North America Non-Tyrosine Kinase Inhibitors market as:

North America Non-Tyrosine Kinase Inhibitors Market: Regional Segment Analysis (Regional Consumption Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):

United States

Canada

Mexico

North America Non-Tyrosine Kinase Inhibitors Market: Product Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):

mTOR Inhibitors
RAF/MEK Inhibitors
CDK Inhibitors

North America Non-Tyrosine Kinase Inhibitors Market: Application Segment Analysis (Consumption Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)

Liver Cancer
Respiratory Cancer
Brain Cancer
Others

North America Non-Tyrosine Kinase Inhibitors Market: Players Segment Analysis (Company and Product introduction, Non-Tyrosine Kinase Inhibitors Sales Volume, Revenue, Price and Gross Margin):

Roche
Eli Lilly
Novartis
Array BioPharma
Nerviano Medical Sciences
Pfizer
Merck KGaA
Astex Pharmaceuticals
Cyclacel Pharmaceuticals
Daiichi Sankyo
Onconova Therapeutics
AstraZeneca
GlaxoSmithKline (GSK)
Carna Biosciences
Celgene Corporation
Eternity Bioscience
Jasco Pharmaceuticals

In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.

Contents

CHAPTER 1 OVERVIEW OF NON-TYROSINE KINASE INHIBITORS

- 1.1 Definition of Non-Tyrosine Kinase Inhibitors in This Report
- 1.2 Commercial Types of Non-Tyrosine Kinase Inhibitors
 - 1.2.1 mTOR Inhibitors
 - 1.2.2 RAF/MEK Inhibitors
 - 1.2.3 CDK Inhibitors
- 1.3 Downstream Application of Non-Tyrosine Kinase Inhibitors
 - 1.3.1 Liver Cancer
 - 1.3.2 Respiratory Cancer
 - 1.3.3 Brain Cancer
 - 1.3.4 Others
- 1.4 Development History of Non-Tyrosine Kinase Inhibitors
- 1.5 Market Status and Trend of Non-Tyrosine Kinase Inhibitors 2013-2023
 - 1.5.1 North America Non-Tyrosine Kinase Inhibitors Market Status and Trend 2013-2023
 - 1.5.2 Regional Non-Tyrosine Kinase Inhibitors Market Status and Trend 2013-2023

CHAPTER 2 NORTH AMERICA MARKET STATUS AND FORECAST BY REGIONS

- 2.1 Market Status of Non-Tyrosine Kinase Inhibitors in North America 2013-2017
- 2.2 Consumption Market of Non-Tyrosine Kinase Inhibitors in North America by Regions
 - 2.2.1 Consumption Volume of Non-Tyrosine Kinase Inhibitors in North America by Regions
 - 2.2.2 Revenue of Non-Tyrosine Kinase Inhibitors in North America by Regions
- 2.3 Market Analysis of Non-Tyrosine Kinase Inhibitors in North America by Regions
 - 2.3.1 Market Analysis of Non-Tyrosine Kinase Inhibitors in United States 2013-2017
 - 2.3.2 Market Analysis of Non-Tyrosine Kinase Inhibitors in Canada 2013-2017
 - 2.3.3 Market Analysis of Non-Tyrosine Kinase Inhibitors in Mexico 2013-2017
- 2.4 Market Development Forecast of Non-Tyrosine Kinase Inhibitors in North America 2018-2023
 - 2.4.1 Market Development Forecast of Non-Tyrosine Kinase Inhibitors in North America 2018-2023
 - 2.4.2 Market Development Forecast of Non-Tyrosine Kinase Inhibitors by Regions 2018-2023

CHAPTER 3 NORTH AMERICA MARKET STATUS AND FORECAST BY TYPES

3.1 Whole North America Market Status by Types

3.1.1 Consumption Volume of Non-Tyrosine Kinase Inhibitors in North America by Types

3.1.2 Revenue of Non-Tyrosine Kinase Inhibitors in North America by Types

3.2 North America Market Status by Types in Major Countries

3.2.1 Market Status by Types in United States

3.2.2 Market Status by Types in Canada

3.2.3 Market Status by Types in Mexico

3.3 Market Forecast of Non-Tyrosine Kinase Inhibitors in North America by Types

CHAPTER 4 NORTH AMERICA MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY

4.1 Demand Volume of Non-Tyrosine Kinase Inhibitors in North America by Downstream Industry

4.2 Demand Volume of Non-Tyrosine Kinase Inhibitors by Downstream Industry in Major Countries

4.2.1 Demand Volume of Non-Tyrosine Kinase Inhibitors by Downstream Industry in United States

4.2.2 Demand Volume of Non-Tyrosine Kinase Inhibitors by Downstream Industry in Canada

4.2.3 Demand Volume of Non-Tyrosine Kinase Inhibitors by Downstream Industry in Mexico

4.3 Market Forecast of Non-Tyrosine Kinase Inhibitors in North America by Downstream Industry

CHAPTER 5 MARKET DRIVING FACTOR ANALYSIS OF NON-TYROSINE KINASE INHIBITORS

5.1 North America Economy Situation and Trend Overview

5.2 Non-Tyrosine Kinase Inhibitors Downstream Industry Situation and Trend Overview

CHAPTER 6 NON-TYROSINE KINASE INHIBITORS MARKET COMPETITION STATUS BY MAJOR PLAYERS IN NORTH AMERICA

6.1 Sales Volume of Non-Tyrosine Kinase Inhibitors in North America by Major Players

6.2 Revenue of Non-Tyrosine Kinase Inhibitors in North America by Major Players

6.3 Basic Information of Non-Tyrosine Kinase Inhibitors by Major Players

6.3.1 Headquarters Location and Established Time of Non-Tyrosine Kinase Inhibitors
Major Players

6.3.2 Employees and Revenue Level of Non-Tyrosine Kinase Inhibitors Major Players
6.4 Market Competition News and Trend

6.4.1 Merger, Consolidation or Acquisition News

6.4.2 Investment or Disinvestment News

6.4.3 New Product Development and Launch

CHAPTER 7 NON-TYROSINE KINASE INHIBITORS MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA

7.1 Roche

7.1.1 Company profile

7.1.2 Representative Non-Tyrosine Kinase Inhibitors Product

7.1.3 Non-Tyrosine Kinase Inhibitors Sales, Revenue, Price and Gross Margin of
Roche

7.2 Eli Lilly

7.2.1 Company profile

7.2.2 Representative Non-Tyrosine Kinase Inhibitors Product

7.2.3 Non-Tyrosine Kinase Inhibitors Sales, Revenue, Price and Gross Margin of Eli
Lilly

7.3 Novartis

7.3.1 Company profile

7.3.2 Representative Non-Tyrosine Kinase Inhibitors Product

7.3.3 Non-Tyrosine Kinase Inhibitors Sales, Revenue, Price and Gross Margin of
Novartis

7.4 Array BioPharma

7.4.1 Company profile

7.4.2 Representative Non-Tyrosine Kinase Inhibitors Product

7.4.3 Non-Tyrosine Kinase Inhibitors Sales, Revenue, Price and Gross Margin of Array
BioPharma

7.5 Nerviano Medical Sciences

7.5.1 Company profile

7.5.2 Representative Non-Tyrosine Kinase Inhibitors Product

7.5.3 Non-Tyrosine Kinase Inhibitors Sales, Revenue, Price and Gross Margin of
Nerviano Medical Sciences

7.6 Pfizer

7.6.1 Company profile

7.6.2 Representative Non-Tyrosine Kinase Inhibitors Product

7.6.3 Non-Tyrosine Kinase Inhibitors Sales, Revenue, Price and Gross Margin of Pfizer

7.7 Merck KGaA

7.7.1 Company profile

7.7.2 Representative Non-Tyrosine Kinase Inhibitors Product

7.7.3 Non-Tyrosine Kinase Inhibitors Sales, Revenue, Price and Gross Margin of Merck KGaA

7.8 Astex Pharmaceuticals

7.8.1 Company profile

7.8.2 Representative Non-Tyrosine Kinase Inhibitors Product

7.8.3 Non-Tyrosine Kinase Inhibitors Sales, Revenue, Price and Gross Margin of Astex Pharmaceuticals

7.9 Cyclacel Pharmaceuticals

7.9.1 Company profile

7.9.2 Representative Non-Tyrosine Kinase Inhibitors Product

7.9.3 Non-Tyrosine Kinase Inhibitors Sales, Revenue, Price and Gross Margin of Cyclacel Pharmaceuticals

7.10 Daiichi Sankyo

7.10.1 Company profile

7.10.2 Representative Non-Tyrosine Kinase Inhibitors Product

7.10.3 Non-Tyrosine Kinase Inhibitors Sales, Revenue, Price and Gross Margin of Daiichi Sankyo

7.11 Onconova Therapeutics

7.11.1 Company profile

7.11.2 Representative Non-Tyrosine Kinase Inhibitors Product

7.11.3 Non-Tyrosine Kinase Inhibitors Sales, Revenue, Price and Gross Margin of Onconova Therapeutics

7.12 AstraZeneca

7.12.1 Company profile

7.12.2 Representative Non-Tyrosine Kinase Inhibitors Product

7.12.3 Non-Tyrosine Kinase Inhibitors Sales, Revenue, Price and Gross Margin of AstraZeneca

7.13 GlaxoSmithKline (GSK)

7.13.1 Company profile

7.13.2 Representative Non-Tyrosine Kinase Inhibitors Product

7.13.3 Non-Tyrosine Kinase Inhibitors Sales, Revenue, Price and Gross Margin of GlaxoSmithKline (GSK)

7.14 Carna Biosciences

7.14.1 Company profile

- 7.14.2 Representative Non-Tyrosine Kinase Inhibitors Product
- 7.14.3 Non-Tyrosine Kinase Inhibitors Sales, Revenue, Price and Gross Margin of Carna Biosciences
- 7.15 Celgene Corporation
 - 7.15.1 Company profile
 - 7.15.2 Representative Non-Tyrosine Kinase Inhibitors Product
 - 7.15.3 Non-Tyrosine Kinase Inhibitors Sales, Revenue, Price and Gross Margin of Celgene Corporation
- 7.16 Eternity Bioscience
- 7.17 Jasco Pharmaceuticals

CHAPTER 8 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF NON-TYROSINE KINASE INHIBITORS

- 8.1 Industry Chain of Non-Tyrosine Kinase Inhibitors
- 8.2 Upstream Market and Representative Companies Analysis
- 8.3 Downstream Market and Representative Companies Analysis

CHAPTER 9 COST AND GROSS MARGIN ANALYSIS OF NON-TYROSINE KINASE INHIBITORS

- 9.1 Cost Structure Analysis of Non-Tyrosine Kinase Inhibitors
- 9.2 Raw Materials Cost Analysis of Non-Tyrosine Kinase Inhibitors
- 9.3 Labor Cost Analysis of Non-Tyrosine Kinase Inhibitors
- 9.4 Manufacturing Expenses Analysis of Non-Tyrosine Kinase Inhibitors

CHAPTER 10 MARKETING STATUS ANALYSIS OF NON-TYROSINE KINASE INHIBITORS

- 10.1 Marketing Channel
 - 10.1.1 Direct Marketing
 - 10.1.2 Indirect Marketing
 - 10.1.3 Marketing Channel Development Trend
- 10.2 Market Positioning
 - 10.2.1 Pricing Strategy
 - 10.2.2 Brand Strategy
 - 10.2.3 Target Client
- 10.3 Distributors/Traders List

CHAPTER 11 REPORT CONCLUSION

CHAPTER 12 RESEARCH METHODOLOGY AND REFERENCE

12.1 Methodology/Research Approach

12.1.1 Research Programs/Design

12.1.2 Market Size Estimation

12.1.3 Market Breakdown and Data Triangulation

12.2 Data Source

12.2.1 Secondary Sources

12.2.2 Primary Sources

12.3 Reference

I would like to order

Product name: Non-Tyrosine Kinase Inhibitors-North America Market Status and Trend Report
2013-2023

Product link: <https://marketpublishers.com/r/N8CA7D10339EN.html>

Price: US\$ 3,480.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer
Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click
button on product page <https://marketpublishers.com/r/N8CA7D10339EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form
below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms
& Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below
and fax the completed form to +44 20 7900 3970

